Palbociclib ( PD-@ ) is an oral , small-molecule inhibitor of cyclin-dependent kinases ( CDKs ) @ and @ with preclinical evidence of growth-inhibitory activity in oestrogen receptor-positive breast cancer cells and synergy with anti-oestrogens .